The valuation trajectory of Doctolib between the first quarter of 2022 and the first quarter of 2026 represents a seminal case study in the maturation of the European HealthTech ecosystem. During this period, the company’s implied market value shifted from a primary funding peak of €5.8 Billion to a secondary transaction valuation of €3.6 Billion, marking a 40% decrease that has sparked extensive debate among industry analysts and institutional investors.

The European HealthTech and MedTech M&A landscape in 2026 is poised for significant strategic acceleration, marking a transition from cautious, volume-driven dealmaking to high-value, transformative transactions. Deal flow is consolidating toward fewer but substantially larger deals, with market participants prioritising scalable technologies with robust clinical validation and AI integration capabilities.